These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17380267)

  • 1. Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.
    Ortega I; Rodriguez M; Suarez E; Perez-Ruixo JJ; Calvo R
    Pharm Res; 2007 Jul; 24(7):1299-308. PubMed ID: 17380267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
    Rowbottom C; Pietrasiewicz A; Tuczewycz T; Grater R; Qiu D; Kapadnis S; Trapa P
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00740. PubMed ID: 33660938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat.
    Rodriguez M; Ortega I; Soengas I; Suarez E; Lukas JC; Calvo R
    J Pharm Pharmacol; 2004 Mar; 56(3):367-74. PubMed ID: 15025862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
    Kharasch ED; Hoffer C; Whittington D
    Br J Clin Pharmacol; 2004 May; 57(5):600-10. PubMed ID: 15089813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
    ten Tije AJ; Synold TW; Spicer D; Verweij J; Doroshow JH; Sparreboom A
    Invest New Drugs; 2003 Aug; 21(3):291-8. PubMed ID: 14578679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and pharmacokinetics of oral and injectable formulations of methadone after intravenous, oral, and intragastric administration in horses.
    Linardi RL; Stokes AM; Keowen ML; Barker SA; Hosgood GL; Short CR
    Am J Vet Res; 2012 Feb; 73(2):290-5. PubMed ID: 22280392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.
    Meissner K; Blood J; Francis AM; Yermolenka V; Kharasch ED
    Anesthesiology; 2014 Dec; 121(6):1281-91. PubMed ID: 25072223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of the injectable formulation of methadone hydrochloride administered orally in horses.
    Linardi RL; Stokes AM; Barker SA; Short C; Hosgood G; Natalini CC
    J Vet Pharmacol Ther; 2009 Oct; 32(5):492-7. PubMed ID: 19754917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) for the solubilization and in vivo delivery of valspodar.
    Binkhathlan Z; Elhasi S; Brocks DR; Lavasanifar A
    Curr Drug Deliv; 2012 Mar; 9(2):164-71. PubMed ID: 22283648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility.
    Vinson RK
    Clin Drug Investig; 2012 Jul; 32(7):487-95. PubMed ID: 22621465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
    Choi JS; Choi I; Choi DH
    Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No influence of ABCB1 haplotypes on methadone dosage requirement.
    Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
    Clin Pharmacol Ther; 2008 May; 83(5):668-9; author reply 669-70. PubMed ID: 18043693
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.
    Hassan HE; Myers AL; Coop A; Eddington ND
    J Pharm Sci; 2009 Dec; 98(12):4928-40. PubMed ID: 19370547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.
    Kukanich B; Lascelles BD; Aman AM; Mealey KL; Papich MG
    J Vet Pharmacol Ther; 2005 Oct; 28(5):461-6. PubMed ID: 16207309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
    Li C; Choi DH; Choi JS
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):99-108. PubMed ID: 22210483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac.
    Bouër R; Barthe L; Philibert C; Tournaire C; Woodley J; Houin G
    Fundam Clin Pharmacol; 1999; 13(4):494-500. PubMed ID: 10456292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
    Choi DH; Choi JS; Li C; Choi JS
    Pharmacol Rep; 2011; 63(6):1574-82. PubMed ID: 22358108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.